Category 2: Recommended for restricted use within the NHS in Scotland.
Approved for treatment of chronic myeloid leukaemia under the overall supervision of haematologists/oncologists, within the context of the current guidelines on this medicine issued by the British Society of Haematology (November 2001).
REASONS FOR ADVICE
Imatinib is the first treatment to offer major cytogenetic responses in chronic myeloid leukaemia. This approach appears to provide a significant advance in the treatment of a hitherto fatal haematological malignancy.
Download detailed advice20KB (PDF)
- Medicine name:
- imatinib (Glivec)
- SMC ID:
- Chronic myeloid leukaemia
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 08 March 2002
SMC advice was superseded by NICE MTA 251: Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012). This advised that standard-dose imatinib (400mg per day for patients in chronic phase) is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML).
NICE MTA 251 was withdrawn in December 2016 but the NICE MTA 251 advice for imatinib remains valid in NHSScotland.